XERS Q3 2018 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$582,000+242.4% YoY

Gross Profit

$582,000100.0% margin

Operating Income

-$15M-2567.5% margin

Net Income

-$15M-2537.3% margin

EPS (Diluted)

$-1.81

QoQ Revenue Growth

-28.9%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$544,000

Balance Sheet

Total Assets

$138M

Total Liabilities

$42M

Stockholders' Equity

$95M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$582,000	$170,000	+242.4%
Gross Profit	$582,000	$170,000	+242.4%
Operating Income	-$15M	-$8M	-97.3%
Net Income	-$15M	-$8M	-96.2%